Gustave Roussy Cancer Campus, Villejuif, France; Institut National de la Santé Et de la Recherche Médicale (INSERM) UMR 1015, ClinicObiome, Équipe Labellisée-Ligue Nationale contre le Cancer, Villejuif, France; Université Paris-Saclay, Ile-de-France, France; Center of Clinical Investigations in Biotherapies of Cancer (BIOTHERIS), Villejuif, France.
Gustave Roussy Cancer Campus, Villejuif, France; Institut National de la Santé Et de la Recherche Médicale (INSERM) UMR 1015, ClinicObiome, Équipe Labellisée-Ligue Nationale contre le Cancer, Villejuif, France; Université Paris-Saclay, Ile-de-France, France.
Immunity. 2024 Sep 10;57(9):2013-2029. doi: 10.1016/j.immuni.2024.07.020. Epub 2024 Aug 15.
The intestinal microbiota determines immune responses against extraintestinal antigens, including tumor-associated antigens. Indeed, depletion or gross perturbation of the microbiota undermines the efficacy of cancer immunotherapy, thereby compromising the clinical outcome of cancer patients. In this review, we discuss the long-distance effects of the gut microbiota and the mechanisms governing antitumor immunity, such as the translocation of intestinal microbes into tumors, migration of leukocyte populations from the gut to the rest of the body, including tumors, as well as immunomodulatory microbial products and metabolites. The relationship between these pathways is incompletely understood, in particular the significance of the tumor microbiota with respect to the identification of host and/or microbial products that regulate the egress of bacteria and immunocytes toward tumor beds.
肠道微生物群决定了针对肠道外抗原(包括肿瘤相关抗原)的免疫反应。事实上,肠道微生物群的耗竭或严重紊乱会削弱癌症免疫疗法的疗效,从而影响癌症患者的临床结局。在这篇综述中,我们讨论了肠道微生物群的远距离效应及其控制抗肿瘤免疫的机制,如肠道微生物向肿瘤的易位、白细胞从肠道向包括肿瘤在内的身体其他部位的迁移,以及免疫调节微生物产物和代谢物。这些途径之间的关系尚未完全了解,特别是肿瘤微生物群对于鉴定宿主和/或微生物产物的意义,这些产物可以调节细菌和免疫细胞向肿瘤床的移出。